Abstract
FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.
| Original language | Italian |
|---|---|
| Pages (from-to) | 313-315 |
| Number of pages | 3 |
| Journal | Bollettino - Lega Italiana contro l'Epilessia |
| Issue number | 106-107 |
| Publication status | Published - 1999 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente. / Specchio, L. M.; La Neve, A.; Spinelli, A.; Boero, G.; Specchio, N.
In: Bollettino - Lega Italiana contro l'Epilessia, No. 106-107, 1999, p. 313-315.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente
AU - Specchio, L. M.
AU - La Neve, A.
AU - Spinelli, A.
AU - Boero, G.
AU - Specchio, N.
PY - 1999
Y1 - 1999
N2 - FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.
AB - FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.
KW - Add-on treatment
KW - Felbamate
KW - Refractory epilepsy
UR - http://www.scopus.com/inward/record.url?scp=0033493886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033493886&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0033493886
SP - 313
EP - 315
JO - Bollettino - Lega Italiana contro l'Epilessia
JF - Bollettino - Lega Italiana contro l'Epilessia
SN - 0394-560X
IS - 106-107
ER -